$2.00 In U.S. Up 230% !, page-11

Prima BioMed up big on positive clinical trial results
May 19 2015, 16:44 ET | About: Prima BioMed Ltd (PBMD) | By: Douglas W. House, SA News Editor

• Thinly traded nano cap Prima BioMed (NASDAQ:PBMD) rockets up on a whopping 135x surge in volume (1.5M shares) in response to its announcement of encouraging data from the Phase 2 CAN-003 trial in ovarian cancer which showed second remission patients treated with CVac demonstrated a significant improvement in overall survival (OS) compared to standard-of-care (SOC) treatment.
• In the second remission population (n=20), median OS was 25.53 months in the SOC cohort but still indeterminable in the CVac cohort after 42 months. The strikingly low hazard ratio of 0.17 implies a median survival advantage of at least 16 months compared to standard-of-care treatment.
• The results are consistent with the statistically significant progression-free survival (PFS) benefit in second remission patients reported in May of last year. Median PFS in the CVac cohort was 12.91 months compared to 4.94 for SOC (p=0.04), implying an eight-month median PFS advantage.
• CVac is an autologous cancer vaccine that stimulates the patient's immune system to target and destroy tumors. The therapy involves isolating white blood cells from the patient's whole blood via leukapheresis. The cells are then matured and treated with mucin 1, a cell surface protein that is overexpressed in epithelial tumors, and then injected just below the skin surface of the patient. The cells enter into the circulation where they activate T cells to target and kill mucin-1-producing cancer cells.
• CVac's development is ongoing.
• Shares are up 10% after hours on robust volume.

362 people get PBMD breaking news and analysis